BRCA1 and breast cancer: Six patients (28.6%) received post-niraparib neoadjuvant chemotherapy (NACT); all patients underwent surgery: 14 patients had BRCA1mut, 6 had BRCA2mut and 1 had BRCA1/2mut; 15 patients (71.4%) had TNBC and 6 patients (28.6%) had hormone-receptor positive (HR+) BC (Supplementary Table 1).